Hecht, Anna
Meyer, Julia A.
Jann, Johann-Christoph
Sockel, Katja
Giagounidis, Aristoteles
Götze, Katharina S.
Letsch, Anne
Haase, Detlef
Schlenk, Richard F.
Haferlach, Torsten
Schafhausen, Philippe
Bug, Gesine
Lübbert, Michael
Thol, Felicitas
Büsche, Guntram
Schuler, Esther
Nowak, Verena
Obländer, Julia
Fey, Stephanie
Müller, Nadine
Metzgeroth, Georgia
Hofmann, Wolf-Karsten
Germing, Ulrich
Nolte, Florian
Reinwald, Mark
Nowak, Daniel
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (NO817/5-2)
Deutsche Krebshilfe (70113953)
Gutermuth Foundation
H.W. & J. Hector Fund (M83)
Dr. Rolf M. Schwiete Fund (Project 20/2016)
José Carreras Leukämie-Stiftung (DJCLS H 03/01)
Celgene
Article History
Received: 17 November 2020
Accepted: 8 March 2021
First Online: 27 April 2021
Declarations
:
: This study was approved by the review boards of all participating institutions as part of the scientific program of the MDS-LE-MON-5 study, EudraCT number: 2008-001866-10, ExternalRef removed: #NCT01081431.
: All patients gave written informed consent.
: The experimental work in this study was partially funded by a research grant from Celgene Inc.